|
|
|
| home > white papers > R&D to Product: How to Reduce Costly Scale-Up Problems - Natoli Engineering Company, Inc. |
|
|
 WHITE PAPERS |
|
Natoli Engineering Company, Inc.
|
|
R&D to Product: How to Reduce Costly Scale-Up Problems
|
|
When scaling a new drug formulation from the development side of R&D into manufacturing, there is often a reality check with respect to process scaleup and performance of the formulation at production levels. Problems with capping/lamination and sticking/ picking are often first realized when a formulation is introduced to a level of compression required to supply market demand.
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
IBM Research and Arctoris Accelerate Closed Loop Drug Discovery with AI and Cloud
Oxford and Zurich – 13 September 2021 – Life Science Newswire –
Today, IBM Research and Arctoris announced they are investigating the
application of AI and automation to accelerate closed loop molecule
discovery. IBM Research has developed RXN for Chemistry, an online
platform leveraging state-of-the-art Natural Language Processing (NLP)
architectures to automate synthetic chemistry.
More info >> |
|
 |
White Papers |
 |
|
Bio/Pharmaceutical Methods: Do your Analytical Methods Hold Up to Regulatory Scrutiny?
Eurofins BioPharma Product Testing
As FDA guidelines evolve and drug products on the market begin to age, bio/pharmaceutical manufacturers face scrutiny of the original methods used to support these products. Therefore, manufacturers must re-evaluate these methods to ensure they comply with current FDA expectations. Some manufacturers are even facing consent decrees imposed by the agency requiring them to bring methods up to current standards within a specified timeframe. This exercise requires significant amounts of time and resources, which many manufacturers do not have since they are focused on getting their next products to market. For that reason, some clients have been turning to Eurofins Lancaster Laboratories for support.
More info >> |
|
|
|
